Key facts
- This page summarizes Cambrian BioPharma Inc's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2026, 17:21.
Cambrian BioPharma Inc - 01 Jun 2026 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SNSE
- Reported as of
- 01 Jun 2026
- Net transaction value
- -$500,543
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2026, 17:21:50 UTC
- Prior SEC filing
- 10 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- Cambrian BioPharma Inc, by: /s/ James Peyer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Cambrian BioPharma Inc filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 01 Jun 2026.
Change
- Previous filing in this sequence was filed on 10 Dec 2025.
- Current net transaction value: -$500,543.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001797409
Primary reporting owner
Cambrian BioPharma Inc
- Relationship
- 10%+ Owner
- Address
- 228 PARK AVENUE S., #66643, NEW YORK
- Signature
- Cambrian BioPharma Inc, by: /s/ James Peyer
- Signature date
- 01 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SNSE
transaction
Common Stock
Sale
- Transaction value
- $490,480
- Shares
- -24,524
- Change %
- -16%
- Price
- $20.00
- Shares after
- 130,618
- Date
- 01 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
SNSE
transaction
Common Stock
Sale
- Transaction value
- $10,063
- Shares
- -476
- Change %
- -0.36%
- Price
- $21.14
- Shares after
- 130,142
- Date
- 01 Jun 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Cambrian BioPharma Inc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.